TABLE 1.
Comparison of the total volume of distribution (V T) of [11C]GSK189254 after placebo and after pitolisant
| Placebo (n = 6) | Pitolisant (n = 6) | |||
|---|---|---|---|---|
| M | SD | M | SD | |
| Cerebellar cortex | 13.1 | 1.6 | 5.0 | 0.9 |
| Occipital cortex | 13.4 | 2.5 | 5.3 | 0.9 |
| Temporal cortex | 16.3 | 2.2 | 5.8 | 1.2 |
| Thalamus | 18.8 | 2.0 | 6.7 | 1.4 |
| Prefrontal cortex | 19.1 | 1.1 | 6.2 | 1.3 |
| Insula cortex | 24.0 | 4.4 | 6.9 | 1.6 |
| Anterior cingulate cortex | 25.9 | 3.4 | 7.4 | 1.7 |
| Caudate | 43.9 | 9.3 | 9.8 | 2.8 |
| Putamen | 46.9 | 9.4 | 10.6 | 3.2 |
Note. [11C]GSK189254 total volume of distribution (V T) in different regions of interest following placebo or a single dose of 40 mg of pitolisant (n = 6). Values of V T after pitolisant were significantly different from values after placebo (P < 0.05) in all the regions. V T is expressed in ml·cm−3.